BC Innovations | Aug 8, 2018
Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) In vitro , cell culture and mouse studies identified a piperazine-based dual MDM2/HDAC6 inhibitor that could help treat NSCLC. Chemical synthesis and in vitro testing of conjugates consisting of analogs...
BC Week In Review | Oct 10, 2016
Company News

City of Hope, NatureWise deal

City of Hope granted NatureWise an exclusive, worldwide license to a patent covering discovery-stage cancer candidates that inhibit histone deacetylase 8 (HDAC8) . City of Hope declined to disclose financial terms, and NatureWise did not respond...
BC Innovations | Mar 17, 2016
Distillery Therapeutics

Therapeutics: Schistosoma mansoni histone deacetylase 8 (SmHDAC8)

Infectious disease INDICATION: Infectious In vitro and parasite studies identified a benzohydroxamate-based SmHDAC8 inhibitor that could help treat schistosomiasis. Chemical synthesis and in vitro testing of benzohydroxamate analogs identified a compound that selectively inhibited SmHDAC8...
BC Innovations | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Histone deacetylase 8 (HDAC8)

Cancer INDICATION: Acute myelogenous leukemia (AML) In vitro and mouse studies suggest inhibiting HDAC8 could help treat AML. In primary human AML leukemic stem cells, an HDAC8 inhibitor decreased proliferation and increased apoptosis compared with...
BC Innovations | Jun 13, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Histone deacetylase 6 (HDAC6); histone deacetylase 8 (HDAC8) In vitro studies suggest dual inhibition of HDAC6 and HDAC8 could help...
BC Innovations | Apr 4, 2013
Cover Story

Closer to class IIa HDAC inhibitors

GlaxoSmithKline plc and its Tempero Pharmaceuticals Inc. spinout have identified selective, first-in-class compounds that bind and inhibit the catalytic domain of class IIa histone deacetylase s, 1 a not-so-well-understood subset of the target family that...
BC Innovations | Dec 6, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Histone deacetylase 8 (HDAC8) In vitro studies identified an HDAC8-selective inhibitor that could help treat cancer. In vitro screening identified a hydroxamate-based molecule that...
BC Innovations | Sep 17, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Histone deacetylase (HDAC) SAR and high throughput screening studies identified cyclic a3b-tetrapeptides as HDAC inhibitors that could help treat cancer. In vitro, the...
BC Innovations | Apr 30, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer Histone deacetylase (^HDAC); ^HDAC1; ^HDAC2; ^HDAC6; ^HDAC8 In vitro studies suggest that a class of boronic acid-based HDAC inhibitors...
BC Week In Review | Feb 18, 2008
Clinical News

Pharmacyclics preclinical data

In vitro, the selectivity of PCI-34051 for histone deacetylase 8 (HDAC8) was 200-1,000 times greater than other HDAC enzymes tested. The HDAC8 inhibitor also induced caspase-dependent apoptosis in cell lines derived from T cell lymphomas...
Items per page:
1 - 10 of 11